Industry

Tenpoint Therapeutics Appoints Stephen S. Lane, MD, as Chief Medical Officer

Eyewire+6h ago2 min read

Tenpoint Therapeutics announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the company’s executive leadership team and oversee clinical development strategy, medical affairs, and pharmacovigilance. Dr. Lane brings more than four decades of experience in ophthalmology, spanning clinical practice, research, and pharmaceutical leadership. He most recently served as Chief Medical Officer and Head of Medical Safety at Alcon. Dr. Lane has held numerous prominent positions, including President of the American Society of Cataract and Refractive Surgery (ASCRS) and member of the Committee of Secretaries at the American Academy of Ophthalmology (AAO). He has also served as a board member and officer of the International Society of Refractive Surgery (ISRS) and as a board member of the Minnesota Academy of Ophthalmology. “Dr. Lane is a highly respected ophthalmology leader whose experience spans clinical practice, product development, and medical leadership at the highest levels of the industry,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. “He is exceptionally well suited to help drive Tenpoint Therapeutics as we advance innovative therapies for the aging eye and enter this next stage of commercial growth.” Dr. Lane currently serves as Chief Executive Officer of the Holland Foundation for Sight Restoration, a nonprofit organization focused on developing centers of excellence for ocular stem cell transplantation and advancing corneal surgery education. He is also a Clinical Professor of Ophthalmology at the University of Minnesota. “I am excited to join Tenpoint Therapeutics at a time of significant opportunity for the company and the field of ophthalmology,” said Dr. Lane. “Tenpoint Therapeutics’ dedication to advancing innovative treatments for the aging eye aligns closely with my passion for improving patient outcomes. I look forward to working with the team to further develop and deliver solutions that address the unmet needs of both patients and the eye care professionals who care for them.” Tenpoint Therapeutics recently announced the US availability of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults. Yuvezzi is the first and only approved dual-agent eye drop that combines carbachol and brimonidine tartrate.

Read full article on Eyewire+

AI Summary

Quick Take

Tenpoint Therapeutics has appointed Dr. Stephen S. Lane, former Chief Medical Officer at Alcon and past President of ASCRS, as its new CMO. Dr. Lane will lead clinical development and medical affairs as the company scales commercial growth for Yuvezzi, the first dual-agent eye drop approved for the treatment of presbyopia.

Why It Matters

Securing a leader of Dr. Lane’s caliber—with deep roots in both high-level industry leadership and organized ophthalmology—signals Tenpoint's intent to aggressively pursue the presbyopia market. While pharmacological treatments for presbyopia have faced adoption hurdles, Tenpoint is positioning its dual-agent approach (carbachol and brimonidine) as a clinical differentiator. Dr. Lane’s extensive background in refractive surgery and medical safety will be critical in refining patient selection protocols and building clinician trust in this emerging therapeutic category.

Key Details

Dr. Stephen S. Lane joins Tenpoint Therapeutics as Chief Medical Officer, overseeing clinical development strategy, medical affairs, and pharmacovigilance.
Dr. Lane brings over 40 years of experience, including his most recent tenure as CMO and Head of Medical Safety at Alcon.
He has held major leadership roles in the field, including President of the American Society of Cataract and Refractive Surgery (ASCRS) and positions within the AAO and ISRS.
The appointment coincides with the U.S. availability of Yuvezzi (carbachol 2.75% and brimonidine tartrate 0.1%), the first approved dual-agent drop for adult presbyopia.
Dr. Lane also serves as CEO of the Holland Foundation for Sight Restoration and is a Clinical Professor of Ophthalmology at the University of Minnesota.

Who's Affected

OphthalmologistsOptometristsRefractive SurgeonsPractice OwnersPharmaceutical Industry Analysts

What's Next

With Dr. Lane overseeing clinical strategy, Tenpoint is expected to focus on the commercial rollout and medical education surrounding Yuvezzi. The industry should watch for upcoming clinical data or educational initiatives aimed at distinguishing their dual-agent formulation from existing single-agent presbyopia drops.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.